Biocon gets 6 observations from USFDA for its Malaysian facility in pre-approval inspection “We are confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the US FDA in the stipulated time,” Biocon spokesperson said.